The role of the gut microbiome in the regulation of astrocytes in Alzheimer's disease

Neurotherapeutics. 2024 Oct;21(6):e00425. doi: 10.1016/j.neurot.2024.e00425. Epub 2024 Jul 25.

Abstract

Alzheimer's disease (AD) is the most common neurodegenerative disorder and is the most common cause of dementia. AD is characterized pathologically by proteinaceous aggregates composed of amyloid beta (Aβ) and tau as well as progressive neurodegeneration. Concurrently with the buildup of protein aggregates, a strong neuroinflammatory response, in the form of reactive astrocytosis and microgliosis, occurs in the AD brain. It has recently been shown that the gut microbiome (GMB), composed of trillions of bacteria in the human intestine, can regulate both reactive astrocytosis and microgliosis in the context of both amyloidosis and tauopathy. Many studies have implicated microglia in these processes. However, growing evidence suggests that interactions between the GMB and astrocytes have a much larger role than previously thought. In this review, we summarize evidence regarding the gut microbiome in the control of reactive astrocytosis in AD.

Keywords: Amyloid; Astrocyte; Gut microbiome; Neuroinflammation; Tau.

Publication types

  • Review

MeSH terms

  • Alzheimer Disease* / metabolism
  • Alzheimer Disease* / microbiology
  • Alzheimer Disease* / pathology
  • Animals
  • Astrocytes* / metabolism
  • Astrocytes* / microbiology
  • Brain / metabolism
  • Brain / microbiology
  • Brain / pathology
  • Gastrointestinal Microbiome* / physiology
  • Gliosis / microbiology
  • Gliosis / pathology
  • Humans